Inventiva Announces A Late Breaker Abstract And Two Additional Abstracts On Its Lead Compound, Lanifibranor, At The AASLD The Liver Meeting 2023
Inventiva Announces A Late Breaker Abstract And Two Additional Abstracts On Its Lead Compound, Lanifibranor, At The AASLD The Liver Meeting 2023
Inventiva 在 2023 年 AASLD 肝臟會議上宣佈了一份關於其主要化合物 Lanifibranor 的最新摘要和另外兩份摘要
The phase II study led by Dr. Kenneth Cusi evaluating lanifibranor in patients with T2D and MASLD was selected as late breaker.
Two additional scientific abstracts from the NATIVE Phase IIb clinical trial evaluating lanifibranor for the treatment of patients with NASH have been selected for presentation. The two abstracts show:
the correlation between the increase of adiponectin under lanifibranor and the improvement of histological and serum markers of NASH severity both in terms of activity and fibrosis.
the improvement of liver histology and markers of cardiometabolic health in patients with NASH treated with lanifibranor, independent of PNPLA3 genotype.
由肯尼思·庫****領導的評估T2D和MASLD患者的拉尼菲布蘭諾的II期研究被選爲晚期突破者。
評估拉尼菲布蘭用於治療NASH患者的NATIVE IIb期臨床試驗的另外兩份科學摘要已被選出進行介紹。這兩份摘要顯示：
在活性和纖維化方面，lanifibranor下脂聯素的增加與NASH嚴重程度的組織學和血清標誌物的改善之間的相關性。
使用 lanifibranor 治療 NASH 患者的肝臟組織學和心臟代謝健康標誌物的改善，與 PNPLA3 基因型無關。
Daix (France), Long...
戴克斯...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間